secwatch.observer — SEC 8-K summary
======================================

Issuer:     IN8BIO, INC. (INAB)
CIK:        0001740279
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0000950170-24-125526
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IN8bio Q3 net loss $7.1M; cash $4.0M; closes $11.6M placement; INB-100/200 updates
--------------------------------------------------------------------------------

- Net loss of $7.1M ($0.15 per share) vs $7.2M loss ($0.23) in Q3 2023.
- Cash $4.0M at Sept 30; closed Oct private placement for $11.6M net proceeds, extending runway into Q1 2026.
- R&D $3.3M (-13% YoY), G&A $2.7M (-21% YoY); severance charges $1.1M from workforce reduction.
- All AML patients in INB-100 remain in CR; FDA provided registrational path; expansion to ~25 patients planned.
- Suspended INB-400 Phase 2 enrollment for newly diagnosed GBM; monitoring continues at SNO and ASH meetings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024125526/0000950170-24-125526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1740279/000095017024125526/inab-20241112.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-125526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer